LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
IQVIA Holdings Inc. - Analyst/Investor Day Dec. 10
HSBC Adjusts Price Target on IQVIA Holdings to $270 From $290 Dec. 04 MT
Nephron Upgrades IQVIA Holdings to Buy, Price Target is $250 Dec. 02 MT
Nephron Research Upgrades IQVIA to Buy, Price Target is $250 Dec. 02 MT
Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating Nov. 26 MT
Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating Nov. 25 MT
Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating Nov. 25 MT
Leerink Adjusts Price Target on IQVIA Holdings to $248 From $260, Maintains Outperform Rating Nov. 19 MT
IQVIA Holdings Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 10:15 AM Nov. 13
Argus Cuts Price Target on IQVIA to $260 From $280 Nov. 06 MT
JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating Nov. 05 MT
UBS Adjusts Price Target on IQVIA to $260 From $300, Maintains Buy Rating Nov. 01 MT
Citigroup Adjusts Price Target on IQVIA to $225 From $250 Nov. 01 MT
Jefferies Adjusts Price Target on IQVIA to $195 From $242 Nov. 01 MT
BTIG Adjusts Price Target on IQVIA to $260 From $290 Nov. 01 MT
Baird Adjusts Price Target on IQVIA to $223 From $256 Nov. 01 MT
Barclays Adjusts Price Target on IQVIA to $255 From $260 Nov. 01 MT
Goldman Sachs Adjusts Price Target on IQVIA to $250 From $280 Nov. 01 MT
Deutsche Bank Adjusts Price Target on IQVIA to $265 From $270 Nov. 01 MT
Evercore ISI Adjusts Price Target on IQVIA to $235 From $265 Nov. 01 MT
Leerink Partners Adjusts Price Target on IQVIA to $260 From $270 Nov. 01 MT
Stifel Adjusts Price Target on IQVIA to $273 From $312 Nov. 01 MT
TD Cowen Adjusts Price Target on IQVIA to $255 From $270 Nov. 01 MT
Truist Cuts Price Target on IQVIA Holdings to $265 From $286, Maintains Buy Rating Nov. 01 MT
Analyst recommendations: Amazon.com, Mastercard, Bristol-Myers Squibb Company, Uber Technologies, Regeneron Pharmaceuticals... Nov. 01Our Logo
Chart Iqvia Holdings Inc.
IQV: Dynamic Chart
Logo Iqvia Holdings Inc.
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Employees
88,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart IQVIA-HOLDINGS-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
203.20USD
Average target price
250.79USD
Spread / Average Target
+23.42%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. IQV Stock
  4. News Iqvia Holdings Inc.
  5. Iqvia Holdings Insider Sold Shares Worth $5,700,340, According to a Recent SEC Filing